Trial Profile
Phase II Trial of Daratumumab for Transplant-Eligible Multiple Myeloma Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Oct 2023
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Autologous stem cell therapy; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 25 Mar 2022 Status changed from suspended to active, no longer recruiting.
- 27 Sep 2021 Status changed from recruiting to suspended.